Peter Sordillo
Chief Tech/Sci/R&D Officer at SignPath Pharma, Inc.
Profile
Peter Sordillo is currently the Chief Medical Officer, Chief Science Officer & VP at SignPath Pharma, Inc. and an Associate Professor at Icahn School of Medicine at Mount Sinai.
He previously worked as an Assistant Professor at Weill Cornell Medical College and an Associate Professor at New York University School of Medicine.
Dr. Sordillo has a graduate and doctorate degree from The Trustees of Columbia University in The City of New York, a graduate degree from New York University, a graduate degree from New York Medical College, and an undergraduate degree from Columbia College (New York).
Peter Sordillo active positions
Companies | Position | Start |
---|---|---|
SignPath Pharma, Inc.
SignPath Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SignPath Pharma, Inc. operates as a development stage biotechnology company. It engages in the research and development of curcumin formulations for the treatment of cancer, neurologic disorders and mitigates drug-induced cardiac arrhythmia. The company was founded by Bruce Meyers in May 15, 2006 and is headquartered in Sandy, UT. | Chief Tech/Sci/R&D Officer | 2017-05-31 |
Icahn School of Medicine at Mount Sinai | Corporate Officer/Principal | - |
Former positions of Peter Sordillo
Companies | Position | End |
---|---|---|
New York University School of Medicine | Corporate Officer/Principal | - |
Weill Cornell Medical College | Corporate Officer/Principal | - |
Training of Peter Sordillo
Columbia College (New York) | Undergraduate Degree |
New York Medical College | Graduate Degree |
New York University | Graduate Degree |
The Trustees of Columbia University in The City of New York | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
SignPath Pharma, Inc.
SignPath Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SignPath Pharma, Inc. operates as a development stage biotechnology company. It engages in the research and development of curcumin formulations for the treatment of cancer, neurologic disorders and mitigates drug-induced cardiac arrhythmia. The company was founded by Bruce Meyers in May 15, 2006 and is headquartered in Sandy, UT. | Commercial Services |
- Stock Market
- Insiders
- Peter Sordillo